Loading
HALO-301 was the phase 3 test of breaking down the dense stroma of pancreatic tumours with a hyaluronidase enzyme so chemotherapy could reach them; response rates went up but survival did not move, and the stroma-busting idea in this form was abandoned.
HALO 109-301 randomised 494 patients (492 analysed: 327 PEGPH20, 165 placebo) whose tumours were hyaluronan-high on a companion assay. Median overall survival was 11.2 months with PEGPH20 against 11.5 months with placebo (hazard ratio 1.00, 95 percent confidence interval 0.80 to 1.27; p 0.97), progression-free survival 7.1 months in both arms (hazard ratio 0.97) and objective response 47 against 36 percent (ratio 1.29). Grade 3 or worse fatigue (16.0 against 9.6 percent), muscle spasms (6.5 against 0.6) and hyponatraemia (8.0 against 3.8) were commoner with PEGPH20. The trial recruited at 15 UK sites (Cambridge, Peterborough, the Beatson Glasgow, Sarah Cannon London, Edinburgh, Clatterbridge, Birmingham, Castle Hill, Coventry, Hammersmith and the Royal Marsden among them). The authors concluded the results did not support further development in metastatic disease and Halozyme closed the programme in 2019.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Desmoplasia (tumour stroma), Gemcitabine + nab-paclitaxel, Nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma.
Shares Gemcitabine + nab-paclitaxel, Nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Nab-paclitaxel, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Eric Van Cutsem, Desmoplasia (tumour stroma), Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma.